A glycine reuptake inhibitor (GRI) is a type of drug which inhibits the reuptake of the neurotransmitter glycine by blocking one or more of the glycine transporters (GlyTs). Examples of GRIs include bitopertin (RG1678), Org 24598, Org 25935, ALX-5407, and sarcosine, which are selective GlyT1 blockers, and Org 25543 and N-arachidonylglycine, which are selective GlyT2 blockers.[1][2] Some weak and/or non-selective GlyT blockers include amoxapine and ethanol (alcohol).[3]
See also[edit]
References[edit]
- ^ Harsing LG, Juranyi Z, Gacsalyi I, Tapolcsanyi P, Czompa A, Matyus P (2006). "Glycine transporter type-1 and its inhibitors". Curr. Med. Chem. 13 (9): 1017–44. doi:10.2174/092986706776360932. PMID 16611082.
- ^ Harvey RJ, Yee BK (November 2013). "Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain". Nat Rev Drug Discov. 12 (11): 866–85. doi:10.1038/nrd3893. PMID 24172334. S2CID 28022131.
- ^ Harald Sitte, Michael Freissmuth (2 August 2006). Neurotransmitter Transporters. Springer Science & Business Media. pp. 472–. ISBN 978-3-540-29784-0.